Barclays
IMUX icon

Barclays’s Immunic IMUX Stock Holding History

Barclays’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-666
Closed -$73K – 7113
2018
Q3 		$73K Buy
+666
New +$1.74M ﹤0.01% 5814
2015
Q3 		– Sell
-22
Closed -$183K – 6935
2015
Q2 		$183K Buy
+22
New +$210K ﹤0.01% 4200

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Barclays's IMUX Position: Q3 2026 in Review

Barclays increased its Immunic (IMUX) stake by 715% in Q3 2026, buying an estimated $48.6K and bringing the position to 4,025 shares worth $37.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4637.

Barclays first reported a position in IMUX in Q2 2014 and has held it in 33 quarters since. The position peaked at $217K in Q4 2021. 15 funds tracked by Wall St. Rank hold IMUX as of Q3 2026.

  • Barclays held 4,025 shares of Immunic worth $37.4K as of Q3 2026.
  • Barclays bought 3,531 Immunic shares in Q3 2026, an estimated $48.6K.
  • Immunic made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4637 holding.
  • Barclays first reported a position in Immunic in Q2 2014 and has held it in 33 quarters since.
  • Barclays's Immunic position peaked at $217K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Immunic as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.